IPC-klasse
Fullmektig i Norge:
Fullmektig i EP:
2007.09.10, US 971144 P
2007.12.13, US 13372
Colman et al.: "Effect of a small molecule inhibitor of the JAK2/STAT3 pathway on self-renewal of glioblastoma stem cells", Journal of Clinical Oncology, vol. 26, no. 15S May 2008 (2008-05), XP002661523, Retrieved from the Internet: URL:http://meeting.ascopubs.org/cgi/conten t/abstract/26/15_suppl/2003?sid=22d20bba-d 0ca-4739-a434-779df098ec93 [retrieved on 2010-10-17] (B1)
ZHOU JIANGBING ET AL: "Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, no. 41, October 2007 (2007-10), pages 16158-16163, XP002661526, ISSN: 0027-8424 -& ZHOU JIANGBING ET AL: "Corrections: Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, no. 49, 4 December 2007 (2007-12-04), XP002662722, (B1)
DESMOND JULIAN C ET AL: "The synthetic furanonaphthoquinone induces growth arrest, apoptosis and differentiation in a variety of leukaemias and multiple myeloma cells", BRITISH JOURNAL OF HAEMATOLOGY, vol. 131, no. 4, November 2005 (2005-11), pages 520-529, XP002661429, ISSN: 0007-1048 (B1)
FRANK DAVID A: "STAT3 as a central mediator of neoplastic cellular transformation", CANCER LETTERS, vol. 251, no. 2, June 2007 (2007-06), pages 199-210, XP022059608, ISSN: 0304-3835 (B1)
HIRAI KEI-ICHI ET AL: "Furanonaphthoquinone analogs possessing preferential antitumor activity compared to normal cells", CANCER DETECTION AND PREVENTION, ELSEVIER SCIENCE, vol. 223, no. 6, 1 January 1999 (1999-01-01), pages 539-550, XP009152976, ISSN: 0361-090X (B1)
JOHNSON FAYE M ET AL: "Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 13, no. 14, 15 July 2007 (2007-07-15) , pages 4233-4244, XP002661521, ISSN: 1078-0432 (B1)
KATOH MASUKO ET AL: "STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer (Review)", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 19, no. 2, 1 February 2007 (2007-02-01), pages 273-278, XP009090900, SPANDIDOS PUBLICATIONS, GR ISSN: 1107-3756 (B1)
KIM KWANG WOON ET AL: "Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation", MOLECULAR CANCER THERAPEUTICS, vol. 5, no. 11, November 2006 (2006-11), pages 2659-2665, XP002661520, ISSN: 1535-7163 (B1)
MARY RIEBER: 'Mcl-1 cleavage and sustained phosphorylation of c-Jun-N-terminal kinase mediate melanoma apoptosis induced by 2-acetyl furanonaphthoquinone: roles of Bcl-2 and p53.' CANCER BIOLOGY & THERAPY vol. 7, no. 8, 01 August 2008, pages 1206 - 1211, XP055078281 ISSN: 1538-4047 (B1)
SUN X ET AL: "Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and STI571", BLOOD, vol. 97, no. 7, 1 January 2001 (2001-01-01), pages 2008-2015, XP001151676, AMERICAN SOCIETY OF HEMATOLOGY, US ISSN: 0006-4971, DOI: 10.1182/BLOOD.V97.7.2008 (B1)
US-A1- 2004 138 189 (B1)
US-A1- 2006 247 318 (B1)
US-A1- 2007 123 502 (B1)
WO-A1-2005/058829 (B1)
WO-A2-00/44774 (B1)
WO-A2-2004/026253 (B1)
WO-A2-2005/033048 (B1)
WO-A2-2005/110477 (B1)
WO-A2-2006/056399 (B1)
WO-A2-2006/113790 (B1)
WO-A2-2007/100640 (B1)
WO-A2-2007/115269 (B1)
WO-A2-2008/077062 (B1)
WO-A2-2008/094321 (B1)
YAO ET AL.: "Experimental study on the growth inhibition of bladder cancer cells by signal conduction blocker AG490", JOURNAL OF CLINICAL UROLOGY, vol. 21, no. 5, May 2006 (2006-05), pages 379-382, XP002661522, (B1)
YAU CINDY Y F ET AL: "Inhibition of integrin-linked kinase by QLT0254 inhibits Akt-dependent pathways and is growth inhibitory in orthotopic primary pancreatic cancer xenografts", CANCER RESEARCH, vol. 65, no. 4, 15 February 2005 (2005-02-15), pages 1497-1504, XP002661524, ISSN: 0008-5472 (B1)
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CHEN, CHENG CHANG ET AL: "Constituents of Markhamia hildebrandtii (Baker) Sprague and their antitumor activity", XP002661423, retrieved from STN Database accession no. 1986:568912 (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
Patent opphørt | Ikke betalt årsavgift |
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Utgående
EP Opphørt for ikke betalt årsavgift (3206)
|
Utgående
EP Påminnelse om ikke betalt årsavgift (3331) (PTEP2200431)
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Registreringsbrev (3210)
|
Utgående
EP Batch Varsel om betaling av første årsavgift (3319)
|
Innkommende
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 16. avg. år (EP) | 2023.09.26 | 5200 | Jing Lei | Betalt og godkjent |
Årsavgift 15. avg. år (EP) | 2022.09.29 | 4850 | Jing Lei | Betalt og godkjent |
Årsavgift 14. avg. år (EP) | 2021.09.15 | 4500 | Jing Lei | Betalt og godkjent |
Årsavgift 13. avg. år (EP) | 2020.08.20 | 4200 | leijing@guozhuan.com | Betalt og godkjent |
Årsavgift 12. avg. år (EP) | 2019.09.10 | 3850 | Jing Lei | Betalt og godkjent |
Årsavgift 11. avg. år (EP) | 2018.08.27 | 3500 | MASTER DATA INC | Betalt og godkjent |
Årsavgift 10. avg. år (EP) | 2017.09.25 | 3200 | 1/DENNEMEYER CO S.A R.L. | Betalt og godkjent |
Årsavgift 9. avg. år (EP) | 2016.09.09 | 2850 | CPA GLOBAL LTD | Betalt og godkjent |
31613018 expand_more expand_less | 2016.09.01 | 5500 | Orsnes Patent ApS | Betalt |
Valideringsgebyr EP-patent
5500 = 1 X 5500
|